TOP > 外国特許検索 > TEST METHOD, GENE MARKER, AND TEST AGENT FOR DIAGNOSING BREAST CANCER

TEST METHOD, GENE MARKER, AND TEST AGENT FOR DIAGNOSING BREAST CANCER NEW

外国特許コード F170009157
整理番号 5212
掲載日 2017年8月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP000340
国際公開番号 WO 2017119510
国際出願日 平成29年1月6日(2017.1.6)
国際公開日 平成29年7月13日(2017.7.13)
優先権データ
  • 特願2016-003090 (2016.1.8) JP
発明の名称 (英語) TEST METHOD, GENE MARKER, AND TEST AGENT FOR DIAGNOSING BREAST CANCER NEW
発明の概要(英語) The present invention provides a test method for diagnosing breast cancer, said method comprising measuring, in a sample containing DNA extracted from a subject, the methylation state of at least one CpG site present in at least one DNA methylation region (DMR) selected from DMRs specific to breast cancer or a breast cancer subtype within the JAK3 gene, RASGRF1 gene, CPXM1 gene, SHF gene, DNM3 gene, CAV2 gene, HOXA10 gene, B3GNT5 gene, ST3GAL6 gene, DACH1 gene, P2RX3 gene, and cg23495581 genome region.
特許請求の範囲(英語) [claim1]
1. Being inspection method for diagnosing the milk cancer, the (1)- below in the DNA content sample which it picked from the subject (12):
(1) state of methylation of the CpG region of specified one or more which exists in the territory inside the human JAK3 gene which is represented with nucleotide arrangement of arrangement number 1;
(2) state of methylation of the CpG region of specified one or more which exists in the territory inside the human RASGRF1 gene which is represented with nucleotide arrangement of arrangement number 2;
(3) state of methylation of the CpG region of specified one or more which exists in the territory inside the human CPXM1 gene which is represented with nucleotide arrangement of arrangement number 3;
(4) state of methylation of the CpG region of specified one or more which exists in the territory inside the human SHF gene which is represented with nucleotide arrangement of arrangement number 4;
(5) state of methylation of the CpG region of specified one or more which exists in the territory inside the human DNM3 gene which is represented with nucleotide arrangement of arrangement number 5;
(6) state of methylation of the CpG region of specified one or more which exists in the territory inside the human CAV2 gene which is represented with nucleotide arrangement of arrangement number 6;
(7) State of methylation of the CpG region of specified one or more which exists in the territory inside the human HOXA10 gene which is represented with nucleotide arrangement of arrangement number 7;
(8) State of methylation of the CpG region of specified one or more which exists in the territory inside the human B3GNT5 gene which is represented with nucleotide arrangement of arrangement number 8;
(9) State of methylation of the CpG region of specified one or more which exists in the territory inside the human ST3GAL6 gene which is represented with nucleotide arrangement of arrangement number 9;
(10) State of methylation of the CpG region of specified one or more which exists in the territory inside the human DACH1 gene which is represented with nucleotide arrangement of arrangement number 10;
(11) State of methylation of the CpG region of specified one or more which exists in the territory inside the human P2RX3 gene which is represented with nucleotide arrangement of arrangement number 11;
(12) State of methylation of the CpG region of specified one or more which exists in the genome DNA territory on the human 8th chromosome which is represented with nucleotide arrangement of arrangement number 12;
From the process which measures the state of methylation of one or more which is selected (process A) it includes, method.
[claim2]
2. In process A, state of methylation of one or more which is selected, the aforementioned (5)- (8) from state and the description above of methylation of one or more which is selected (9) the - (12) from it features that state of methylation of one or more which is selected is measured from the aforementioned (1)-(4), in claim 1 method of statement.
[claim3]
3. In process A, the aforementioned (1)- (12) it features that state of the methylation which is shown is measured, in claim 1 or 2 method of statement.
[claim4]
4. Respectively, being the gene of 2 or more where it exists in the separate chromosome, inside it can become the factor which reflects the quantity of the whole DNA the process which furthermore measures the quantity of the standard gene (process B) it includes, either of the claim 1-3 in one section method of statement.
[claim5]
5. The gene which can become the aforementioned internal standard, frequency of copy several mutations in the milk cancer cell is under 5%, in claim 4 method of statement.
[claim6]
6. It features that the gene of 1 or more where it is selected from one group where the gene which can become the aforementioned internal standard consists of the CREM gene, the GLYATL3 gene, the ELMOD3 gene and the KLF9 gene is included, in claim 4 method of statement.
[claim7]
7. It features that the gene which can become the aforementioned internal standard is the CREM gene, the GLYATL3 gene, the ELMOD3 gene and the KLF9 gene, in claim 4 method of statement.
[claim8]
8. DNA which was picked from the aforementioned subject, features that it is circulation DNA in the blood, either of the claim 1-7 in one section method of statement
[claim9]
9. In the aforementioned process A, measurement of state of methylation, is done by measuring the areru density of each gene where the CpG region of the said specified one or more is methylated, either of the claim 1-8 in one section method of statement.
[claim10]
10. In the aforementioned process B, the quantity of the internal standard gene, features that it is areru density of the said gene, either of the claim 4-9 in one section method of statement.
[claim11]
11. In the aforementioned process A, the aforementioned (1)- (12) state of the methylation which is shown is measured, the fact that the quantity of the CREM gene, the GLYATL3 gene, the ELMOD3 gene and the KLF9 gene is measured in the aforementioned process B, is included, being method of statement in claim 9 or 10,
Logarithm of the respective areru density which is obtained (C) by the aforementioned process A,
Arithmetical mean of logarithm of the respective areru density which is obtained by the aforementioned process A,
The process which calculates the final value for deciding the milk cancer of logarithm of areru density of the gene which can become the aforementioned internal standard which is obtained by the aforementioned process B making use of the arithmetic expression which multiplies specified factor arithmetical mean;
Furthermore it includes, method.
[claim12]
12. Being the gene marker for diagnosing the milk cancer,
(1)- below (12):
(1) the said gene fragment which includes the CpG region of one or more which exists in the territory inside the human JAK3 gene which is represented with nucleotide arrangement of arrangement number 1;
(2) the said gene fragment which includes the CpG region of one or more which exists in the territory inside the human RASGRF1 gene which is represented with nucleotide arrangement of arrangement number 2;
(3) the said gene fragment which includes the CpG region of one or more which exists in the territory inside the human CPXM1 gene which is represented with nucleotide arrangement of arrangement number 3;
(4) the said gene fragment which includes the CpG region of one or more which exists in the territory inside the human SHF gene which is represented with nucleotide arrangement of arrangement number 4;
(5) the said gene fragment which includes the CpG region of one or more which exists in the territory inside the human DNM3 gene which is represented with nucleotide arrangement of arrangement number 5;
(6) the said gene fragment which includes the CpG region of one or more which exists in the territory inside the human CAV2 gene which is represented with nucleotide arrangement of arrangement number 6;
(7) The said gene fragment which includes the CpG region of one or more which exists in the territory inside the human HOXA10 gene which is represented with nucleotide arrangement of arrangement number 7;
(8) The said gene fragment which includes the CpG region of one or more which exists in the territory inside the human B3GNT5 gene which is represented with nucleotide arrangement of arrangement number 8;
(9) The said gene fragment which includes the CpG region of one or more which exists in the territory inside the human ST3GAL6 gene which is represented with nucleotide arrangement of arrangement number 9;
(10) The said gene fragment which includes the CpG region of one or more which exists in the territory inside the human DACH1 gene which is represented with nucleotide arrangement of arrangement number 10;
(11) The said gene fragment which includes the CpG region of one or more which exists in the territory inside the human P2RX3 gene which is represented with nucleotide arrangement of arrangement number 11;
(12) The said gene fragment which includes the CpG region of one or more which exists in the genome DNA territory on the human 8th chromosome which is represented with nucleotide arrangement of arrangement number 12;
From gene fragment of one or more which is selected is included, the gene marker.
[claim13]
13. The aforementioned (1)- (12) gene fragment,
(1) during nucleotide arranging of arrangement number 1, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 16-534;
(2) during nucleotide arranging of arrangement number 2, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 59-345;
(3) during nucleotide arranging of arrangement number 3, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 41-400;
(4) during nucleotide arranging of arrangement number 4, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 150-460;
(5) during nucleotide arranging of arrangement number 5, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 118-590;
(6) during nucleotide arranging of arrangement number 6, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 115-566;
(7) During nucleotide arranging of arrangement number 7, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 641-1011;
(8) During nucleotide arranging of arrangement number 8, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 1116-1595;
(9) During nucleotide arranging of arrangement number 9, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 40-448;
(10) During nucleotide arranging of arrangement number 10, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 330-824;
(11) During nucleotide arranging of arrangement number 11, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 225-535;
(12) During nucleotide arranging of arrangement number 12, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 164-822;
So it is, in claim 12 the gene marker of statement.
[claim14]
14. The aforementioned (1)- (12) gene fragment,
(1) during nucleotide arranging of arrangement number 1, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 116-434;
(2) during nucleotide arranging of arrangement number 2, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 159-245;
(3) during nucleotide arranging of arrangement number 3, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 141-300;
(4) during nucleotide arranging of arrangement number 4, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 251-359;
(5) during nucleotide arranging of arrangement number 5, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 218-490;
(6) during nucleotide arranging of arrangement number 6, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 215-484;
(7) During nucleotide arranging of arrangement number 7, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 741-911;
(8) During nucleotide arranging of arrangement number 8, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 1216-1495;
(9) During nucleotide arranging of arrangement number 9, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 140-348;
(10) During nucleotide arranging of arrangement number 10, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 430-724;
(11) During nucleotide arranging of arrangement number 11, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 326-435;
(12) During nucleotide arranging of arrangement number 12, the said gene fragment which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 264-722;
So it is, in claim 12 the gene marker of statement.
[claim15]
15. Inside for the density of the whole DNA being the gene marker which can become standard, at least it includes one which is selected gene or the fragment from the group which consists of the CREM gene, the GLYATL3 gene, the ELMOD3 gene and the KLF9 gene, the gene marker.
[claim16]
16. It features that it uses combining with the gene marker of claim 15 statement, either of the claim 12-14 in one section the gene marker of statement.
[claim17]
17. Being the inspection medicine for diagnosing the milk cancer,
(1)- below (12):
(1) the territory where the CpG region of one or more which exists in the territory inside the human JAK3 gene which is represented with nucleotide arrangement of arrangement number 1 is included;
(2) the territory where the CpG region of one or more which exists in the territory inside the human RASGRF1 gene which is represented with nucleotide arrangement of arrangement number 2 is included;
(3) the territory where the CpG region of one or more which exists in the territory inside the human CPXM1 gene which is represented with nucleotide arrangement of arrangement number 3 is included;
(4) the territory where the CpG region of one or more which exists in the territory inside the human SHF gene which is represented with nucleotide arrangement of arrangement number 4 is included;
(5) the territory where the CpG region of one or more which exists in the territory inside the human DNM3 gene which is represented with nucleotide arrangement of arrangement number 5 is included;
(6) the territory where the CpG region of one or more which exists in the territory inside the human CAV2 gene which is represented with nucleotide arrangement of arrangement number 6 is included;
(7) The CpG region of one or more which exists in the territory inside the human HOXA10 gene which is represented with nucleotide arrangement of arrangement number 7 the territory;
(8) The territory where the CpG region of one or more which exists in the territory inside the human B3GNT5 gene which is represented with nucleotide arrangement of arrangement number 8 is included;
(9) The territory where the CpG region of one or more which exists in the territory inside the human ST3GAL6 gene which is represented with nucleotide arrangement of arrangement number 9 is included;
(10) The territory where the CpG region of one or more which exists in the territory inside the human DACH1 gene which is represented with nucleotide arrangement of arrangement number 10 is included;
(11) The territory where the CpG region of one or more which exists in the territory inside the human P2RX3 gene which is represented with nucleotide arrangement of arrangement number 11 is included;
(12) The territory where the CpG region of one or more which exists in the genome DNA territory on the human 8th chromosome which is represented with nucleotide arrangement of arrangement number 12 is included;
From it can detect the methylation of the specified CpG region in the territory of one or more which is selected, primer set of one or more is included, the inspection medicine.
[claim18]
18. The aforementioned (1)- (12) territory,
(1) during nucleotide arranging of arrangement number 1, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 16-534 is included;
(2) during nucleotide arranging of arrangement number 2, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 59-345 is included;
(3) during nucleotide arranging of arrangement number 3, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 41-400 is included;
(4) during nucleotide arranging of arrangement number 4, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 150-460 is included;
(5) during nucleotide arranging of arrangement number 5, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 118-590 is included;
(6) during nucleotide arranging of arrangement number 6, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 115-566 is included;
(7) During nucleotide arranging of arrangement number 7, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 641-1011 is included;
(8) During nucleotide arranging of arrangement number 8, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 1116-1595 is included;
(9) During nucleotide arranging of arrangement number 9, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 40-448 is included;
(10) During nucleotide arranging of arrangement number 10, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 330-824 is included;
(11) During nucleotide arranging of arrangement number 11, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 225-535 is included;
(12) During nucleotide arranging of arrangement number 12, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 164-822 is included;
So it is, in claim 17 the inspection medicine of statement.
[claim19]
19. The aforementioned (1)- (12) territory,
(1) during nucleotide arranging of arrangement number 1, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 116-434 is included;
(2) during nucleotide arranging of arrangement number 2, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 159-245 is included;
(3) during nucleotide arranging of arrangement number 3, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 141-300 is included;
(4) during nucleotide arranging of arrangement number 4, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 251-359 is included;
(5) during nucleotide arranging of arrangement number 5, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 218-490 is included;
(6) during nucleotide arranging of arrangement number 6, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 215-484 is included;
(7) During nucleotide arranging of arrangement number 7, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 741-911 is included;
(8) During nucleotide arranging of arrangement number 8, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 1216-1495 is included;
(9) During nucleotide arranging of arrangement number 9, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 140-348 is included;
(10) During nucleotide arranging of arrangement number 10, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 430-724 is included;
(11) During nucleotide arranging of arrangement number 11, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 326-435 is included;
(12) In the nucleotide arrangement limits of arrangement number 12, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 264-722 is included;
So it is, in claim 17 the inspection medicine of statement.
[claim20]
20. The aforementioned (1)- (12) the primer set which can detect the methylation of the specified CpG region in each territory which is shown respectively is included, in claim 19 the inspection medicine of statement.
[claim21]
21. (1A) below - (12A):
(1A) Bi- sulphite processing the sequential chain of the human JAK3 gene inner territory which is represented with nucleotide arrangement of arrangement number 1, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 13 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 14 which can;
(2A) Bi- sulphite processing the sequential chain of the human RASGRF1 gene inner territory which is represented with nucleotide arrangement of arrangement number 2, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 15 which can bi- sulphite processing the opposite chain of the said gene inner territory which can, the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 16 which can;
(3A) Bi- sulphite processing the sequential chain of the human CPXM1 gene inner territory which is represented with nucleotide arrangement of arrangement number 3, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 17 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 18 which can;
(4A) Bi- sulphite processing the sequential chain of the human SHF gene inner territory which is represented with nucleotide arrangement of arrangement number 4, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 19 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 20 which can;
(5A) Bi- sulphite processing the sequential chain of the human DNM3 gene inner territory which is represented with nucleotide arrangement of arrangement number 5, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 21 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 22 which can;
(6A) Bi- sulphite processing the sequential chain of the human CAV2 gene inner territory which is represented with nucleotide arrangement of arrangement number 6, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 23 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 24 which can;
(7A) Bi- sulphite processing the sequential chain of the human HOXA10 gene inner territory which is represented with nucleotide arrangement of arrangement number 7, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 25 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 26 which can;
(8A) Bi- sulphite processing the sequential chain of the human B3GNT5 gene inner territory which is represented with nucleotide arrangement of arrangement number 8, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 27 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 28 which can;
(9A) Bi- sulphite processing the sequential chain of the human ST3GAL6 gene inner territory which is represented with nucleotide arrangement of arrangement number 9, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 29 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 30 which can;
(10A) Bi- sulphite processing the sequential chain of the human DACH1 gene inner territory which is represented with nucleotide arrangement of arrangement number 10, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 31 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 32 which can;
(11A) Bi- sulphite processing the sequential chain of the human P2RX3 gene inner territory which is represented with nucleotide arrangement of arrangement number 11, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 33 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 34 which can;
(12A) Bi- sulphite processing the sequential chain of the genome DNA territory on the human 8th chromosome which is represented with nucleotide arrangement of arrangement number 12, bi- sulphite processing the opposite chain of the territory or the said gene inner territory which includes the CpG region of one or more which, exists during nucleotide arranging of the arrangement number 35 which can the territory where it includes the CpG region of one or more which exists during nucleotide arranging of the arrangement number 36 which can;
From it can detect the methylation of the specified CpG region in the territory of one or more which is selected, primer set of one or more is included, in claim 17 the inspection medicine of statement.
[claim22]
22. The description above (1A) - (12A) territory,
(1A) During nucleotide arranging of arrangement number 13, during nucleotide arranging of the territory or the arrangement number 14 which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 16-534, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 9-527 is included;
(2A) During nucleotide arranging of arrangement number 15, during nucleotide arranging of the territory or the arrangement number 16 which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 59-345, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 658-944 is included;
(3A) During nucleotide arranging of arrangement number 17, during nucleotide arranging of the territory or the arrangement number 18 which includes the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 41-400, the territory where the CpG region of one or more which exists in the territory where it is shown with the nucleotide number 558-917 is included;
(...)
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • TOI MASAKAZU
  • SATO FUMIAKI
  • SAJI SHIGEHIRA
  • TOMITA NATSUE
国際特許分類(IPC)
指定国 (WO2017119510)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記「問合せ先」まで直接お問い合わせください。

PAGE TOP

close
close
close
close
close
close